Anti-Idiotypic Antibody Development Services-Tekbiotech-Yeast and Phage Display CRO, Expert in Nano-body and Antibody Drug Development

Services

Inquiry and ordering

Name*
Phone*
Email*
Product*
Content*

Anti-Idiotypic Antibody Development Services

Anti-idiotypic antibodies are antibodies that specifically bind to a unique site on the variable region of another antibody (typically an antibody drug). Anti-idiotypic antibodies are widely used in drug development and serve as key tools for establishing pharmacokinetic (PK) analytical methods, which are used to quantitatively detect the concentrations of therapeutic antibody drugs in the blood in their various states (free, bound, and total). Anti-idiotypic antibodies are also used as positive controls in anti-drug antibody (ADA) assays to assess a drug’s immunogenicity (i.e., the risk of inducing the production of anti-drug antibodies in the human body).

TekBiotech has been dedicated to antibody development and research for many years and is able to provide clients with high-quality anti-idiotypic antibody development services. TekBiotech has accumulated extensive experience in the development of anti-idiotypic antibodies. Leveraging a variety of established antibody discovery technologies—including phage display, yeast display, hybridoma technology, and single B-cell sorting—the company has established a comprehensive anti-idiotypic antibody discovery platform. This platform enables TekBiotech to provide clients with high-affinity, high-specificity, and high-sensitivity anti-idiotypic antibody development services across multiple species (including mice, rabbits, sheep, goats, cattle, camelids, and others). Additionally, TekBiotech can customize antibody development and detection protocols tailored to clients’ downstream detection needs, helping to resolve challenges encountered during project development.

█ Anti-Idiotypic Antibody Development Services

The antigen-binding region of an antibody generally consists of several complementarity-determining regions (CDRs). An anti-idiotypic antibody is an antibody capable of directly recognizing and binding to the variable region of another antibody—that is, the aforementioned CDR regions. Using phage display technology, TekBiotech is able to provide clients with comprehensive, one-stop anti-idiotypic antibody development services. Following complete lysis of animal spleen cells or peripheral blood lymphocytes with TRIzol, TekBiotech uses phage display technology to construct natural, semi-synthetic, and fully synthetic phage display antibody libraries for clients (effective library size > 10?, library diversity > 90%, insertion rate > 90%). We design optimized screening protocols based on the characteristics of the screening antigen and the target antibody to obtain anti-idiotypic antibodies with high affinity and high specificity, meeting the requirements of downstream experimental applications. Additionally, leveraging TekBiotech’s recombinant protein fermentation platform, we can scale up antibody production to meet clients’ needs for large-scale antibody production. TekBiotech’s anti-idiotypic antibody development process is as follows (using phage display technology as an example):

Figure 1: Procedure for the production of anti-idiotypic antibodies using phage display technology

█ Types of Anti-Idiotypic Antibody Development Services

TekBiotech provides high-quality, comprehensive anti-idiotypic antibody development services covering all stages, from early-stage antigen design and synthesis, animal immunization, and antibody library construction (using various established antibody development platforms such as phage display and hybridoma technology) to customized antibody library screening, in vitro detection, in vivo antibody level measurement, and antibody process scale-up. TekBiotech offers anti-idiotypic antibody development services in the following three categories:

Antibody Type	Antigen-Blocking/Neutralizing	Non-Blocking/Non-Neutralizing	Complex-Specific
Antibody structure diagram
Features	Antigen-binding site specificity	Non-antigen-binding site specificity	Drug–target complex specificity
Antigen-Binding Properties	Blocking/Neutralizing	Non-Blocking	Non-Blocking
Applications	Detection of free antibody drug concentration	Detection of total antibody drug concentration	Detection of drug–target complex concentration

█ Advantages of Anti-Idiotypic Antibody Development Services


One-Stop Solution	Customized Screening Solutions	Development of Antibodies Across Multiple Species	Mature downstream detection platforms	Various Antibody Development Technologies
Comprehensive services ranging from early-stage antigen design and synthesis, antibody screening, and validation to process scale-up	Diverse screening solutions for different types of anti-idiotypic antibodies	A wide variety of species are available, including mice, rabbits, sheep, goats, cattle, and camelids (alpaca, llama, and camel).	In vitro binding assays, in vivo antibody level assays, and pharmacokinetic analyses	Phage display technology, yeast display technology, hybridoma technology, single B-cell sorting technology, etc.